Status:
TERMINATED
PINNACLE® DM RSA Study
Lead Sponsor:
DePuy Orthopaedics
Conditions:
Osteoarthritis
Degenerative Arthritis
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
The primary objective is to establish the mean superior cup migration of the PINNACLE® Dual Mobility Construct using model-based RSA over the first two years post-implantation. The primary endpoint is...
Eligibility Criteria
Inclusion
- Individuals requiring primary THA for:
- a severely painful and/or disabled joint (typically due to non-inflammatory degenerative joint disease).
- failed previous hip surgery.
- or dislocation risks.
- Individuals who are able to speak, read and comprehend the informed patient consent document and willing and able to provide informed patient consent for participation in the study and have authorized the transfer of his/her information to DePuy Synthes.
- Individuals who are willing and able to return for follow-up as specified by the study protocol.
- Individuals who are a minimum age of 21 years at the time of consent.
- Individuals who are willing and able to complete the Subject Hip Outcomes questionnaires as specified by the study protocol.
- \-
Exclusion
- Individuals have active local or systemic infection.
- Individuals who have loss of musculature, neuromuscular compromise or vascular deficiency in the affected limb rendering the procedure unjustified.
- Individuals with poor bone quality, such as osteoporosis, where in the surgeon's opinion, there could be considerable migration of the prosthesis or a significant chance of bone fracture and/or the lack of adequate bone to support the implant(s).
- Individuals with Charcot's or Paget's disease.
- Individuals who, in the judgement of the investigator, would not be a candidate for protocol allowable components to be used for their THA.
- Women who are pregnant or lactating.
- Individuals who have had a contralateral hip that was implanted less than 6 months prior to the time of consent into this study or individuals that expect to have a contralateral hip implanted in the 6 months following the time of consent into this study.
- Individuals that have amputations in either leg that would impact rehabilitation following surgery.
- Individuals who are bedridden per the Investigators determination
- Individuals that have participated in a clinical investigation with an investigational product (drug or device) in the last three months.
- Individuals currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
- Individuals, in the opinion of the Investigator, who are drug or alcohol abusers or have a psychological disorder that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.
- Individuals diagnosed and taking prescription medications to treat a muscular disorder that limits mobility due to sever stiffness and pain such as fibromyalgia or polymyalgia.
- Subject has a medical condition with less than 2 years life expectancy.
- Individual has a BMI \>45 kg/m2.
- Individuals who require revision arthroplasty and have a well-fixed non-DePuy Synthes femoral stem or a well-fixed DePuy Synthes femoral stem that does not have a polished neck
Key Trial Info
Start Date :
October 6 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 9 2023
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT05357664
Start Date
October 6 2022
End Date
February 9 2023
Last Update
April 18 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Concordia Joint Replacement Group, Concordia Hip and Knee Institute & University of Manitoba
Winnipeg, Manitoba, Canada
2
QEII Health Sciences Centre & Dalhousie University
Halifax, Nova Scotia, Canada
3
London Health Sciences Centre
London, Ontario, Canada